Company profilePharmaceutical#373 of 1,318 in Pakistan1 DRAP alert

MAX PHARMACEUTICALS

Pharmaceutical company · 46 brands · 42 molecules

46 registered products 19 pharmaceutical brands 42 distinct molecules 1 DRAP alert

Company overview

46
registered products
19
pharmaceutical brands
42
distinct molecules
0
therapeutic classes
1
DRAP alerts

MAX PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 46 product registrations across 42 distinct molecules. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by MAX

2 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Top molecules by brand count

Cetirizine2 brands
Ibuprofen2 brands
Mecobalamin2 brands
Piroxicam-Beta-Cyclodextrin2 brands
Loratadine2 brands

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO2 products · Rs 237.5 – Rs 261.24
Median across source: Rs 249.37

Regulatory record

1 alert in the DRAP feed we track.

Recall Alert: Drug Product; Ceficure 400mg Capsules (Batch # C-737) by M/s Max Pharmaceuti
2022-11-04

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SHROOQ PHARMACEUTICALS holds 21 molecules not in this portfolio
AcitretinAcyclovirAcyclovir Inf/OralCefiximeCiprofloxacinDiclofenac
BIO LABS (PVT) LTD. holds 139 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
GENOME PHARMACEUTICALS (PVT) LTD holds 113 molecules not in this portfolio
AcitretinAmlodipineAnastrazoleAnastrozoleAprepitantArtemether

Get the full profile for MAX

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.